甜梦口服液联合帕罗西汀治疗围绝经期抑郁症的临床观察

发布时间：2018-12-28 07:05

【摘要】：目的:观察甜梦口服液联合帕罗西汀治疗围绝经期抑郁症的疗效和安全性。方法:85例围绝经期抑郁症女性患者随机分为对照组(41例)和观察组(44例)。对照组患者每日早餐后口服盐酸帕罗西汀片20 mg,每日1次;观察组患者在对照组治疗的基础上给予甜梦口服液10 mL,每日早晚各1次。两组均连用8周。观察两组患者的临床疗效,治疗前后围绝经期综合量表(Kupperman)评分、汉密尔顿抑郁量表(HAMD)评分、脑源性神经营养因子(BDNF)水平及不良反应发生情况。结果:对照组和观察组各有1、2例患者失访。两组患者总有效率、不良反应发生率比较,差异均无统计学意义(P0.05)。治疗后,两组患者Kupperman评分、HAMD评分均显著低于同组治疗前,随时间延长逐渐降低,且观察组患者治疗第8周时Kupperman评分、治疗第2周时HAMD评分均显著低于对照组;两组患者BDNF水平均显著高于同组治疗前,随时间延长逐渐升高,且观察组显著高于对照组,差异均有统计学意义(P0.05或P0.01)。结论:甜梦口服液联合帕罗西汀治疗围绝经期抑郁症的疗效和安全性与单用帕罗西汀相当,但在改善症状、升高BDNF方面优于单用帕罗西汀。
[Abstract]:Objective: to observe the efficacy and safety of Tianmeng oral liquid combined with paroxetine in the treatment of postmenopausal depression. Methods: 85 female patients with peri-menopausal depression were randomly divided into control group (41 cases) and observation group (44 cases). The patients in the control group were treated with paroxetine hydrochloride once a day for 20 mg, after breakfast, while the patients in the observation group were treated with sweet dream oral liquid once a day for 10 mL,. Both groups were treated for 8 weeks. The clinical efficacy, (Kupperman) score, (HAMD) score of Hamilton depression scale, the level of brain-derived neurotrophic factor (BDNF) and the incidence of adverse reactions were observed before and after treatment. Results: there were 12 cases in control group and 2 cases in observation group. There was no significant difference in the total effective rate and the incidence of adverse reactions between the two groups (P0.05). After treatment, the Kupperman score and HAMD score of the two groups were significantly lower than those of the same group before treatment, and gradually decreased with the prolongation of time. The Kupperman score of the observation group was significantly lower than that of the control group at the 8th week of treatment and the HAMD score at the second week of treatment. The level of BDNF in the two groups was significantly higher than that in the same group before treatment, and gradually increased with the prolongation of time, and the observation group was significantly higher than the control group, the difference was statistically significant (P0.05 or P0.01). Conclusion: the efficacy and safety of Tianmeng oral liquid combined with paroxetine in the treatment of peri-menopausal depression is similar to that of paroxetine alone, but it is superior to paroxetine alone in improving symptoms and increasing BDNF.
【作者单位】：咸宁市中心医院药剂科;咸宁市中心医院神经内科;
【分类号】：R749.4

【相似文献】